SCHEMBL5660720

SCHEMBL5660720

NC(=O)c1cc(O)c(O)c([N+](=O)[O-])c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.41
MAPT P10636 2/20 0.41
PMP22 Q01453 2/20 0.41
BLM P54132 1/20 0.41
COMT P21964 2/20 0.41
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
CDK2 P24941 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
S100A4 P26447 1/20 0.39
MEN1 O00255 1/20 0.39
TTR P02766 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27825688 0.83 CDK2 (0.51) CYP3A4MAPTPMP22COMTALDH1A1
SCHEMBL28709886 0.78 ALDH1A1 (0.57) CYP3A4MAPTPMP22ALDH1A1KMT2A
SCHEMBL28412179 0.74 GRIN2D (0.43) CYP3A4MAPTPMP22BLMCOMT
SCHEMBL6376194 0.73 KDM4E (0.44) MAPTBLMALDH1A1KMT2ALMNA
SCHEMBL156116 0.72 KDM4E (0.46) CYP3A4MAPTPMP22ALDH1A1KMT2A
SCHEMBL6207406 0.72 CYP3A4 (0.58) CYP3A4MAPTPMP22BLMALDH1A1
SCHEMBL27725375 0.72 ALDH1A1 (0.50) CYP3A4MAPTPMP22BLMALDH1A1
SCHEMBL27713898 0.72 COMT (0.57) COMTALDH1A1
SCHEMBL27530393 0.71 ALDH1A1 (0.46) CYP3A4MAPTALDH1A1KMT2ALMNA
SCHEMBL667585 0.71 TSHR (0.54) CYP3A4MAPTPMP22BLMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017181383-A1 HEPATITIS C VIRUS INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-10-26 WO disclosed
CN-101336247-B Antiviral nucleosides HOFFMANN LA ROCHE 2013-01-23 CN disclosed
CN-102424698-A Modified 2' and 3' -nucleoside produgs for treating flaviridae infections CENTRE NAT RECH SCIENT (FR) 2012-04-25 CN disclosed
CN-101663284-A Macrocyclic compounds as hcv ns3 protease inhibitors NOVARTIS AG 2010-03-03 CN disclosed
CN-101541826-A Macrocyclic HCV inhibitors and their uses NOVARTIS AG (CH) 2009-09-23 CN disclosed
CN-101469009-A Methods and compositions for treating hepatitis c virus IDENIX CAYMAN LTD (KY) 2009-07-01 CN disclosed
CN-101466728-A HCV inhibitors comprising beta amino acids and their uses NOVARTIS AG (CH) 2009-06-24 CN disclosed
CN-101367856-A Methods and compositions for treating hepatitis c virus IDENIX CAYMAN LTD (KY) 2009-02-18 CN disclosed
CN-100402545-C Methods and compositions for treating hepatitis c virus IDENNIKOS KY CO LTD (VG) 2008-07-16 CN disclosed
CN-101115725-A 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation UNIV EMORY (US) 2008-01-30 CN disclosed
EP-1438054-A4 METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES USING 4'-MODIFIED NUCLEOSIDE IDENIX CAYMAN LTD (KY) 2006-07-26 EP disclosed
EP-1438054-A1 METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES USING 4'-MODIFIED NUCLEOSIDE Idenix (Cayman) Limited (KY) 2004-07-21 EP disclosed
CN-1443191-A Methods and compositions for treating hepatitis c virus IDENNIKOS KY CO LTD (KY) 2003-09-17 CN disclosed
WO-2003026675-A1 METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES USING 4'-MODIFIED NUCLEOSIDE IDENIX (CAYMAN) LIMITED (KY) 2003-04-03 WO disclosed